Pharmsintez's loss under RAS for 9 months of 2025 amounted to ₽121.2 million, a decrease of 0.5% compared to ₽121.8 million in the previous year. Revenue decreased by 18.3% to ₽101.3 million from ₽124 million a year earlier.